Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
197.20B
Market cap197.20B
Price-Earnings ratio
25.73
Price-Earnings ratio25.73
Dividend yield
2.60%
Dividend yield2.60%
Average volume
3.13M
Average volume3.13M
High today
$368.74
High today$368.74
Low today
$330.00
Low today$330.00
Open price
$354.19
Open price$354.19
Volume
5.90M
Volume5.90M
52 Week high
$368.75
52 Week high$368.75
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

With a market cap of 197.2B, Amgen(AMGN) trades at $365.00. The stock has a price-to-earnings ratio of 25.73 and currently yields dividends of 2.6%.

During the trading session on 2026-02-05, Amgen(AMGN) shares reached a daily high of $368.74 and a low of $330.00. At a current price of $365.00, the stock is +10.6% higher than the low and still -1.0% under the high.

Trading volume for Amgen(AMGN) stock has reached 5.9M, versus its average volume of 3.13M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $368.75 and a low of $261.43.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $368.75 and a low of $261.43.

AMGN News

Simply Wall St 3h
Is Amgen Offering Fair Value After Strong Multi Year Share Price Gains

If you are wondering whether Amgen's current share price gives you fair value for your money, this article will walk through what the numbers say and where valu...

Is Amgen Offering Fair Value After Strong Multi Year Share Price Gains
Nasdaq 3h
Stock Market News for Feb 5, 2026

U.S. stock markets closed mixed on Wednesday as sector rotation by market participants continued. Investors remained concerned about the significantly overstret...

Stock Market News for Feb 5, 2026
The Motley Fool 12h
Stock Market Today, Feb. 4: AMD Plunges Over 17% As Tech Fallout Continues

On Feb. 4, 2026, AMD’s AI-chip stumble rattled the Nasdaq while defensive Dow names steadied a suddenly nervous Wall Street. The S&P 500 (^GSPC 0.51%) fell 0.5...

Stock Market Today, Feb. 4: AMD Plunges Over 17% As Tech Fallout Continues

Analyst ratings

48%

of 33 ratings
Buy
45.5%
Hold
48.5%
Sell
6.1%

More AMGN News

TipRanks 19h
Amgen’s FORTITUDE-301 Cancer Trial Completion: What Investors Should Watch in Bemarituzumab’s Next Act

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen’s latest update on its FORTITUDE-301 trial offers investors a clearer view of the c...

Benzinga 20h
Amgen Posts Q4 Beat, Recent Label Updates Suggest Upside To 2026 Estimates

Amgen Inc (NASDAQ:AMGN) reported better-than-expected fourth-quarter revenues and earnings, while witnessing "strength across key drivers (Repatha, Uplizna), ev...

Amgen Posts Q4 Beat, Recent Label Updates Suggest Upside To 2026 Estimates
Nasdaq 20h
Dow Movers: IBM, AMGN

In early trading on Wednesday, shares of Amgen topped the list of the day's best performing Dow Jones Industrial Average components, trading up 3.4%. Year to da...

Dow Movers: IBM, AMGN
TipRanks 21h
Amgen price target raised to $360 from $335 at RBC Capital

RBC Capital raised the firm’s price target on Amgen (AMGN) to $360 from $335 and keeps an Outperform rating on the shares. The company reported strong Q4 on bot...

TipRanks 22h
Amgen price target raised to $420 from $389 at TD Cowen

TD Cowen raised the firm’s price target on Amgen (AMGN) to $420 from $389 and keeps a Buy rating on the shares. The firm updated its model following Q4 results...

Simply Wall St 1d
Amgen Drops Eczema Drug Pact As Investors Weigh R&D Focus And Valuation

Amgen (NasdaqGS:AMGN) has ended its collaboration with Kyowa Kirin on the eczema drug rocatinlimab. Rights to develop and commercialize rocatinlimab have been...

Amgen Drops Eczema Drug Pact As Investors Weigh R&D Focus And Valuation
TipRanks 1d
Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating

Analyst Geoff Meacham from Citi maintained a Hold rating on Amgen and keeping the price target at $315.00. Geoff Meacham has given his Hold rating due to a com...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.